Vergote IB, et al. – Analysts gauged cabozantinib in a cohort of ovarian carcinoma patients as part of phase 2 randomised discontinuation trial (RDT) with cohorts from nine different tumour types. In patients with ovarian carcinoma, cabozantinib exhibited clinical activity, with acceptable toxicities, based on objective response rate (ORR) and regression of tumour target lesions.